BRCA 1 & 2 Mutation in Cancer Markets 2017 - Forecasts to 2027 for 18 Major Markets

Dublin, Nov. 30, 2017 -- The "BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027" report has been added to Research and Markets' offering.

It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility gene) germline mutations confer a higher risk of developing ovarian or breast cancer in women that carry the mutation. However, it has also been established that BRCA1 and BRCA2 mutations also confer higher risk of developing cancers such as prostate, pancreatic, stomach and colorectal in individuals that carry the mutations.

This report provides the current prevalent population for BRCA1 & BRCA2 mutations in cancer populations across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Saudi Arabia, Japan, China, Argentina, Brazil, Mexico, India, South Africa and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, several of the main cancers with BRCA1 and BRCA2 mutation have been quantified and presented alongside the overall prevalence figures.

BRCA1/2 mutations are most often associated with the following cancers:

• Breast
• Ovarian
• Pancreatic
• Prostate
• Stomach

And less frequently with the following cancers:

• CRC
• Malignant melanoma
• Kidney cancer
  

Reasons to Buy:

• Able to quantify patient populations in global BRCA1 and BRCA2 mutations market to target the development of future products, pricing strategies and launch plans
• Gain further insight into the prevalence of the BRCA1 and BRCA2 mutations by cancer type and identify patient segments with high potential
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
• Provide a level of understanding on the impact of the mutation on the prevalent population for specific cancer types
• Gain an understanding of the specific markets that have the largest number of BRCA1 and BRCA2 mutation patients

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions/Features Associated With the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Brca1 & Brca2 Mutations in Cancer Populations
10. Brca Mutations by Type of Cancer
11. Abbreviations Used in the Report
12. Other Publications
13. Online Patient-Based Databases
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix
    

For more information about this report visit https://www.researchandmarkets.com/research/qjtpdv/brca_1_and_2

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Oncology Drugs